A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Authors:
Open Access
- 11 December 2015
- journal article
- review article
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 15 (12) , 1020-1029
Abstract
Anadolu Kardiyoloji Dergisi, Anadolu Kardiyol Derg, The Anatolian Journal of Cardiology, Anatol J Cardiol, Cardiology, Cardiovascular Medicine, Surgery, Pediatric Cardiology, AngiologyKeywords
This publication has 50 references indexed in Scilit:
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) StudyCirculation, 2013
- Ischemic Stroke in an Obese Patient Receiving DabigatranNew England Journal of Medicine, 2013
- Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill PatientsNew England Journal of Medicine, 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementNew England Journal of Medicine, 2010
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialThe Lancet, 2010
- Effect of Obesity on the Pharmacokinetics of Drugs in HumansClinical Pharmacokinetics, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementNew England Journal of Medicine, 2009